缺血性卒中辅助静脉阿加曲班或依替巴肽治疗
这项在美国57个中心开展的3期、三组、适应性、单盲、随机对照试验纳入发病3小时内接受静脉溶栓的急性缺血性卒中患者,随机给予阿加曲班、依替巴肽或安慰剂。结果显示辅助阿加曲班或依替巴肽未减少卒中后残疾,且与死亡率升高相关。
要点
- 急性缺血性卒中静脉溶栓后辅助阿加曲班或依替巴肽未减少90天残疾。
- 阿加曲班组90天死亡率24%、依替巴肽组12%,均高于安慰剂组8%。
- 三组症状性颅内出血发生率相似(阿加曲班4%、依替巴肽3%、安慰剂2%)。
核心结论
- 在发病3小时内接受静脉溶栓的急性缺血性卒中患者中,辅助静脉阿加曲班或依替巴肽未减少卒中后残疾,且与死亡率升高相关。
研究设计与样本
- 3期、三组、适应性、单盲、随机对照临床试验,在美国57个中心开展。
- 共514例患者被分配接受阿加曲班(59例)、依替巴肽(227例)或安慰剂(228例)。
- 纳入发病3小时内接受静脉溶栓的急性缺血性卒中患者,在溶栓开始后75分钟内给予阿加曲班、依替巴肽或安慰剂。
- 所有患者均接受静脉溶栓(70%接受阿替普酶,30%接受替奈普酶),225例(44%)接受血管内取栓。
- 主要疗效结局为集中裁定的90天效用加权改良Rankin量表评分(范围0至10分,评分越高结局越好);主要安全结局为随机化后36小时内症状性颅内出血。
主要发现
- 90天时,效用加权改良Rankin量表平均(±SD)评分:阿加曲班组5.2±3.7,依替巴肽组6.3±3.2,安慰剂组6.8±3.0。
- 阿加曲班优于安慰剂的后验概率为0.002(效用加权改良Rankin量表评分后验平均差值-1.51±0.51),依替巴肽优于安慰剂的后验概率为0.041(后验平均差值-0.50±0.29)。
- 症状性颅内出血发生率三组相似:阿加曲班组4%,依替巴肽组3%,安慰剂组2%。
- 90天死亡率:阿加曲班组24%、依替巴肽组12%,均高于安慰剂组8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear. METHODS: We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United States. Patients with acute ischemic stroke who had received intravenous thrombolysis within 3 hours after symptom onset were assigned to receive intravenous argatroban, eptifibatide, or placebo within 75 minutes after the initiation of thrombolysis. The primary efficacy outcome, the utility-weighted 90-day modified Rankin scale score (range, 0 to 10, with higher scores reflecting better outcomes), was assessed by means of centralized adjudication. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after randomization. RESULTS: A total of 514 patients were assigned to receive argatroban (59 patients), eptifibatide (227 patients), or placebo (228 patients). All the patients received intravenous thrombolysis (70% received alteplase, and 30% received tenecteplase), and 225 patients (44%) underwent endovascular thrombectomy. At 90 days, the mean (±SD) utility-weighted modified Rankin scale scores were 5.2±3.7 with argatroban, 6.3±3.2 with eptifibatide, and 6.8±3.0 with placebo. The posterior probability that argatroban was better than placebo was 0.002 (posterior mean difference in utility-weighted modified Rankin scale score, -1.51±0.51) and that eptifibatide was better than placebo was 0.041 (posterior mean difference, -0.50±0.29). The incidence of symptomatic intracranial hemorrhage was similar in the three groups (4% with argatroban, 3% with eptifibatide, and 2% with placebo). Mortality at 90 days was higher in the argatroban group (24%) and the eptifibatide group (12%) than in the placebo group (8%). CONCLUSIONS: In patients with acute ischemic stroke treated with intravenous thrombolysis within 3 hours after symptom onset, adjunctive treatment with intravenous argatroban or eptifibatide did not reduce poststroke disability and was associated with increased mortality. (Funded by the National Institute of Neurological Disorders and Stroke; MOST ClinicalTrials.gov number, NCT03735979.).
引用
- Adeoye O, Broderick J, Derdeyn CP, et al. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. N Engl J Med. 2024. PMID: 39231343. doi:10.1056/NEJMoa2314779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。